<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>survival analysis | Dominic Magirr</title>
    <link>/categories/survival-analysis/</link>
      <atom:link href="/categories/survival-analysis/index.xml" rel="self" type="application/rss+xml" />
    <description>survival analysis</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Fri, 10 Jul 2020 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/img/icon-192.png</url>
      <title>survival analysis</title>
      <link>/categories/survival-analysis/</link>
    </image>
    
    <item>
      <title>Non-proportional hazards in immuno-oncology: is an old perspective needed?</title>
      <link>/post/non-proportional-hazards-in-immuno-oncology-is-an-old-perspective-needed/</link>
      <pubDate>Fri, 10 Jul 2020 00:00:00 +0000</pubDate>
      <guid>/post/non-proportional-hazards-in-immuno-oncology-is-an-old-perspective-needed/</guid>
      <description>


&lt;p&gt;In my opinion, many phase III trials in immuno-oncology are 10–20 % larger than they need (ought) to be.&lt;/p&gt;
&lt;p&gt;This is because the method we use for the primary analysis doesn’t match what we know about how these drugs work.&lt;/p&gt;
&lt;p&gt;Fixing this doesn’t require anything fancy, just old-school stats from the 1960s.&lt;/p&gt;
&lt;p&gt;In this &lt;a href=&#34;https://arxiv.org/abs/2007.04767&#34;&gt;new preprint&lt;/a&gt; I try to explain how I think it should be done.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
